Identificación de biomarcadores predictivos de respuesta al tratamiento con R-CHOP en linfoma B difuso de célula grande (LBDCG)

Heredero Gómez, Ana (2019). Identificación de biomarcadores predictivos de respuesta al tratamiento con R-CHOP en linfoma B difuso de célula grande (LBDCG). Proyecto Fin de Carrera / Trabajo Fin de Grado, E.T.S. de Ingeniería Agronómica, Alimentaria y de Biosistemas (UPM), Madrid.

Description

Title: Identificación de biomarcadores predictivos de respuesta al tratamiento con R-CHOP en linfoma B difuso de célula grande (LBDCG)
Author/s:
  • Heredero Gómez, Ana
Contributor/s:
  • Sánchez-Beato Gómez, Margarita
  • Vicente Carbajosa, Jesús
Item Type: Final Project
Degree: Grado en Biotecnología
Date: September 2019
Subjects:
Faculty: E.T.S. de Ingeniería Agronómica, Alimentaria y de Biosistemas (UPM)
Department: Biotecnología - Biología Vegetal
Creative Commons Licenses: Recognition - No derivative works - Non commercial

Full text

[img]
Preview
PDF - Requires a PDF viewer, such as GSview, Xpdf or Adobe Acrobat Reader
Download (5MB) | Preview

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for approximately 25-35% of them. It is a heterogeneous disease with a variable clinical course that is currently treated with a combination of immuno and chemotherapy (R-CHOP: rituximab + cyclofosfamide, doxorubicin, vincristine and prednisolone). Although the inclusion of immunotherapy (Rituximab) has meant a before and after in the treatment of patients with lymphoma, obtaining complete responses of up to 40-50%, however, a substantial part of the patients relapses, which results in 3-year survival rates of only 30%, and the underlying molecular causes are not yet well known. Therefore, it is relevant to improve the knowledge of the genetic alterations responsible for the refractoriness to the treatment, which finally should lead to new therapeutic proposals. In this project, massive sequencing and bioinformatic analysis are used to: 1) to test the bioinformatic tools, referred to the variant calling and alignment method, with better performance for the detection of said genetic alterations. 2) To detect, identify and study the alterations responsible for the resistance to treatment in relapsed or refractory DLBCL and, similarly, the alterations inherent in ABC or GCB profiles of patients with DLBCL. The purpose of this later biological study is the identification of possible early prognostic biomarkers for this type of lymphoma.

More information

Item ID: 57374
DC Identifier: http://oa.upm.es/57374/
OAI Identifier: oai:oa.upm.es:57374
Deposited by: Biblioteca ETSI Agrónomos
Deposited on: 21 Nov 2019 12:40
Last Modified: 21 Nov 2019 12:40
  • Logo InvestigaM (UPM)
  • Logo GEOUP4
  • Logo Open Access
  • Open Access
  • Logo Sherpa/Romeo
    Check whether the anglo-saxon journal in which you have published an article allows you to also publish it under open access.
  • Logo Dulcinea
    Check whether the spanish journal in which you have published an article allows you to also publish it under open access.
  • Logo de Recolecta
  • Logo del Observatorio I+D+i UPM
  • Logo de OpenCourseWare UPM